<DOC>
	<DOCNO>NCT01483469</DOCNO>
	<brief_summary>This open label , non-randomized , parallel group study evaluate [ 11C ] -RO5011232 radiotracer brain mGlu5 receptor occupancy investigate binding RO49917523 human mGlu5 brain receptor steady-state healthy volunteer . In Parts I , II III , positron emission tomography ( PET ) assessments specific uptake radiotracer whole body dosimetry make intravenous injection [ 11C ] -RO5011232 . In Part IV , subject receive RO4917523 orally daily 14 day receive three single intravenous bolus injection [ 11C ] -RO5011232 . The anticipated time study treatment 4 week .</brief_summary>
	<brief_title>A Human Proof Concept Study 11C-RO5011232 Radiotracer Study Binding RO4917523 Human mGlu5 Brain Receptor Steady-State Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male female volunteer determine medical history , physical examination , 12lead ECG , routine clinical laboratory measurement Age 18 65 year inclusive Body mass index ( BMI ) 18 to30 kg/m2 inclusive body weight least 50 kg Appropriate body size ( le 195 cm [ 6 foot 5 inch ] ) order accommodate whole body scan History presence clinically significant psychiatric condition , evaluate psychiatrist enrolment History head trauma prolonged loss consciousness ( &gt; 10 minute ) neurological condition history migraine headache Contraindications MRI procedure ( Part I , III IV ) Subjects suffer claustrophobia would unable undergo magnetic resonance imaging ( MRI ) PET scan Positive pregnancy test screen day precede PET scan Lactating woman Positive hepatitis B , hepatitis C HIV infection Any history alcohol drug abuse within last 6 month Regular smoker nicotine user ( &gt; 10 cigarette per day ) Participation investigational drug device study within three month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>